There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Abbott Labs (ABT – Research Report) and eFFECTOR Therapeutics (EFTR – Research Report) with bullish sentiments.
Abbott Labs (ABT)
Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Abbott Labs on January 26 and set a price target of $125.00. The company’s shares closed last Friday at $112.01, close to its 52-week high of $115.83.
According to TipRanks.com, Wise is a 4-star analyst with an average return of
Currently, the analyst consensus on Abbott Labs is a Strong Buy with an average price target of $126.15, representing an 11.4% upside. In a report issued on January 15, Wells Fargo also maintained a Buy rating on the stock with a $131.00 price target.
See today’s best-performing stocks on TipRanks >>
eFFECTOR Therapeutics (EFTR)
In a report issued on January 26, Benjamin Burnett from Stifel Nicolaus maintained a Buy rating on eFFECTOR Therapeutics, with a price target of $21.00. The company’s shares closed last Friday at $10.55, close to its 52-week low of $8.45.
According to TipRanks.com, Burnett has 0 stars on 0-5 stars ranking scale with an average return of
eFFECTOR Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $51.00, which is a 461.1% upside from current levels. In a report issued on January 16, Mizuho Securities also maintained a Buy rating on the stock with a $7.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ABT:
